Oral Micronized Progesterone Pediatric (Under 12) Dosing

FDA Labeling and Regulatory Status in Pediatric Patients

Oral micronized progesterone carries no FDA-approved indication for children under 12 years of age. The drug's labeling explicitly states that safety and effectiveness have not been established in pediatric populations. This regulatory gap means every prescription written for a child under 12 is off-label.

Why No Pediatric Approval Exists

The absence of pediatric labeling reflects the drug's development history. Prometrium received FDA approval in 1998 for two adult indications: secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens 1. The PEPI Trial (N=875) demonstrated that micronized progesterone provided endometrial protection comparable to medroxyprogesterone acetate while preserving a more favorable HDL cholesterol profile in postmenopausal women 1. No equivalent trial has been conducted in children.

The Pediatric Research Equity Act Gap

The Pediatric Research Equity Act (PREA) of 2003 requires manufacturers to study certain drugs in pediatric populations, but progesterone's original approval predates this legislation. The FDA's pediatric labeling database does not list oral micronized progesterone among drugs with completed pediatric studies. Generic manufacturers have similarly not pursued pediatric data packages.

Off-Label Prescribing Framework

Off-label use is legal and sometimes medically necessary. The American Academy of Pediatrics has acknowledged that off-label prescribing accounts for a substantial portion of pediatric pharmacotherapy, with estimates ranging from 50% to 75% of drugs used in hospitalized children lacking specific pediatric labeling 2. This does not, however, reduce the clinician's obligation to document a clear therapeutic rationale.

Clinical Scenarios Where Pediatric Use May Be Considered

The rare situations prompting consideration of oral micronized progesterone in children under 12 involve disorders of pubertal timing, adrenal steroidogenesis, or gonadal development. Each scenario demands a pediatric endocrinologist's direct involvement.

Precocious Puberty

Central precocious puberty (CPP), defined as onset of secondary sexual characteristics before age 8 in girls or age 9 in boys, affects approximately 1 in 5,000 to 10,000 children 3. GnRH agonists (leuprolide, histrelin) remain the standard first-line treatment. Progesterone is not a recommended therapy for CPP in the Endocrine Society's 2009 clinical practice guideline 3.

In isolated cases where GnRH agonist therapy is contraindicated or refused, some pediatric endocrinologists have used oral micronized progesterone to suppress breakthrough uterine bleeding. This approach is anecdotal. No published trial supports it as primary or adjunctive CPP therapy.

Congenital Adrenal Hyperplasia

Children with 21-hydroxylase deficiency CAH produce inadequate cortisol and aldosterone while overproducing adrenal androgens 4. Standard treatment centers on glucocorticoid and mineralocorticoid replacement. Progesterone, as a steroid precursor that accumulates proximal to the enzymatic block, is generally not administered exogenously in CAH.

Select cases involving atypical enzyme deficiencies or disorders of sex development (DSD) with a uterus present may involve progesterone supplementation. The Endocrine Society's 2010 CAH guideline does not include oral micronized progesterone in its pediatric treatment algorithms.

Hypothalamic Amenorrhea in Older Children

Girls approaching age 12 with functional hypothalamic amenorrhea secondary to chronic illness, extreme exercise, or nutritional deficit occasionally receive cyclic progesterone to induce withdrawal bleeding. This scenario overlaps the pediatric-adolescent boundary. Most published protocols use medroxyprogesterone acetate rather than micronized progesterone in this population, though micronized formulations may be preferred when lipid-neutral effects are desired 1.

Dosing Approaches When Off-Label Use Proceeds

No consensus dosing guideline exists for oral micronized progesterone in children under 12. The approaches described below are drawn from case reports, extrapolated pharmacokinetic data, and expert opinion. They are not validated by controlled trials.

Weight-Based Estimation

Adult dosing of Prometrium is fixed at 200 mg nightly for endometrial protection or 400 mg nightly for 10 days (cyclic) for secondary amenorrhea 5. In adult women weighing approximately 60 to 80 kg, this produces a weight-normalized range of roughly 2.5 to 6.7 mg/kg/day.

Pediatric extrapolation, when attempted, typically starts at 2 to 5 mg/kg/day. A 25 kg child at 2 mg/kg/day would receive 50 mg nightly. A specialist may titrate upward based on clinical response and serum progesterone levels.

Capsule Formulation Limitations

Prometrium is available only as 100 mg and 200 mg oil-filled soft gelatin capsules. The capsules cannot be split or crushed reliably because the drug is dissolved in peanut oil within the gelatin shell. This creates practical dosing barriers for small children.

Compounding pharmacies can prepare oral micronized progesterone suspensions or custom-dose capsules. When compounding is used, the prescriber must verify the pharmacy's USP 795/800 compliance and confirm the bioavailability of the compounded formulation, as absorption characteristics may differ from the commercially available product 6.

Peanut Oil Allergy Consideration

The Prometrium capsule shell contains peanut oil. Peanut allergy prevalence in U.S. Children is approximately 2.5%, according to FARE data reported through NIAID-funded surveys 7. Children with confirmed peanut allergy must receive a compounded peanut-oil-free preparation or an alternative progestin entirely.

Cyclic vs. Continuous Administration

In adult HRT, micronized progesterone is given either continuously (100 to 200 mg nightly) or cyclically (200 mg nightly for 12 to 14 days per month). The PEPI Trial used 200 mg/day for 12 days/month in its cyclic arm 1.

Pediatric use, when it occurs, more commonly follows a cyclic pattern to induce periodic withdrawal bleeding in girls with a uterus who require endometrial shedding. The duration and frequency of cycling should be determined by the treating specialist based on the child's specific condition and pubertal status.

Pharmacokinetics in Children

Oral micronized progesterone pharmacokinetics have been studied almost exclusively in adult women. The sparse pediatric pharmacokinetic data that exist come from vaginal rather than oral formulations and from adolescents rather than pre-pubertal children.

Absorption and First-Pass Metabolism

In adults, oral micronized progesterone undergoes extensive first-pass hepatic metabolism. Peak serum concentrations occur approximately 2 to 4 hours after dosing, with absolute bioavailability estimated at 6% to 10% when taken with food 6. Taking the capsule at bedtime after a snack improves absorption by 25% to 50% compared with fasting administration.

Children's hepatic enzyme activity per kilogram of body weight is generally higher than in adults. CYP3A4, the primary enzyme metabolizing progesterone, reaches adult levels by approximately age 1 and may exceed adult activity on a per-kilogram basis through mid-childhood 8. This suggests that children could metabolize oral progesterone faster than adults, potentially requiring weight-adjusted doses at the higher end of the estimated range to achieve comparable serum levels.

Metabolite Considerations

Oral progesterone produces several neuroactive metabolites, most notably allopregnanolone (3α-hydroxy-5α-pregnan-20-one). Allopregnanolone acts as a positive allosteric modulator of GABA-A receptors, producing the sedative and anxiolytic effects associated with bedtime dosing in adults 9.

The implications of allopregnanolone exposure in developing pediatric brains have not been formally studied. The GABA-A receptor system undergoes significant maturation during childhood, and the neurological effects of exogenous neuroactive steroids in this population remain unknown. This represents a significant knowledge gap that should factor into risk-benefit discussions with families.

Monitoring Requirements for Pediatric Patients

Any child under 12 receiving off-label oral micronized progesterone requires a monitoring protocol that exceeds what is standard for adult patients. Growth and development surveillance must be layered on top of standard safety labs.

Growth and Pubertal Development

Tanner staging should be assessed at each visit, typically every 3 to 6 months. Linear growth velocity must be tracked using age- and sex-specific growth charts, with any deviation from the child's established percentile triggering re-evaluation of therapy 3.

Bone age radiographs (left hand and wrist) at baseline and every 6 to 12 months help detect premature skeletal maturation. A bone age advancing more than 1 year beyond chronological age warrants reassessment of the treatment plan.

Laboratory Monitoring

Baseline and periodic laboratory evaluation should include:

• Serum progesterone level (trough, drawn in the morning after a bedtime dose) to confirm therapeutic range
• Hepatic transaminases (ALT, AST) at baseline, 3 months, then every 6 months, since oral progesterone undergoes extensive hepatic metabolism
• Lipid panel at baseline and annually, given progesterone's potential lipid effects, though the PEPI Trial showed micronized progesterone was lipid-neutral in adults 1
• Fasting glucose and insulin in children with obesity or metabolic risk factors
• LH, FSH, and estradiol when treating pubertal disorders to assess gonadotropin suppression

Sedation and CNS Effects

The allopregnanolone-mediated sedation seen in adults occurs in children as well. Parents should be counseled to administer the medication at bedtime. Morning drowsiness, dizziness, or behavioral changes should be reported promptly. No validated pediatric sedation scoring tool specific to progesterone exists, so clinicians rely on caregiver-reported symptom diaries 9.

Safety Signals and Adverse Effect Profile

The adverse effect profile of oral micronized progesterone in adults includes drowsiness, dizziness, headache, breast tenderness, abdominal bloating, and mood changes. The FDA prescribing information lists these based on adult clinical trial data exclusively.

Known Risks Extrapolated to Children

Drowsiness is the most commonly reported adverse effect in adults, occurring in approximately 8% to 15% of patients in clinical trials. In children, CNS effects could be more pronounced due to the developing blood-brain barrier and GABA-A receptor system differences 9.

Hepatic effects warrant particular attention. While clinically significant hepatotoxicity from oral micronized progesterone is rare in adults, children's smaller hepatic reserve and developing metabolic pathways make liver function monitoring non-negotiable.

What We Do Not Know

Long-term effects of exogenous progesterone on pediatric bone mineral density accrual, neurocognitive development, and future reproductive function have not been studied. The absence of evidence is not evidence of absence. Clinicians should disclose these unknowns during informed consent discussions.

The Women's Health Initiative demonstrated increased breast cancer risk with combined estrogen-progestin therapy in postmenopausal women 10, but these findings involved medroxyprogesterone acetate in adults and cannot be directly extrapolated to micronized progesterone in children. The E3N French cohort study (N=80,377) found no significant increase in breast cancer risk with micronized progesterone specifically, though follow-up was limited to adults 11.

When to Refer and When to Avoid

Prescribing oral micronized progesterone to a child under 12 should trigger referral to, or originate from, a pediatric endocrinologist.

Absolute Contraindications in Children

The following situations preclude use:

• Known or suspected pregnancy (theoretical only in this age group, but relevant for older pre-adolescents)
• Active liver disease or hepatic dysfunction
• Known peanut allergy (for Prometrium brand; compounded alternatives may be used)
• Undiagnosed vaginal bleeding
• History of hormone-sensitive malignancy

Situations Favoring Alternative Agents

Medroxyprogesterone acetate (MPA) has more published pediatric data than micronized progesterone, particularly in precocious puberty management, though GnRH agonists remain first-line 3. Norethindrone acetate is another synthetic progestin with more extensive pediatric-relevant literature. The choice of micronized over synthetic progestins in children should be justified by a specific clinical reason, such as lipid-sensitivity or intolerance to synthetic agents.

The Role of Informed Consent and Shared Decision-Making

Prescribing off-label medications to children carries heightened medicolegal and ethical responsibilities. The American Academy of Pediatrics recommends that off-label pediatric prescribing include explicit documentation of the evidence basis, therapeutic rationale, and informed consent discussion 2.

What Parents Need to Know

Families should understand that oral micronized progesterone is not FDA-approved for children under 12, that dosing is estimated rather than validated, that long-term developmental effects are unknown, and that alternative treatments with more pediatric data may exist. These conversations should be documented in the medical record.

Documentation Requirements

The prescribing record should include the specific diagnosis prompting off-label use, the evidence or expert reasoning supporting the choice of micronized progesterone over alternatives, the dosing rationale, the monitoring plan, and confirmation that informed consent was obtained from the parent or guardian.

Pediatric endocrinologists treating rare conditions with progesterone are encouraged to report outcomes through case series or registries to build the evidence base that formal trials have not yet provided.